Tables
- TABLE 1
Comparison of the results on phenotypic and genotypic resistance to antituberculosis drugs, Mexico, 2010–2017
Phenotypic results (n=112)# Genotypic results (n=57)# κ (95% CI) Fluoroquinolone resistant 26/111 (23.4%) 12/57 (21.1%) 0.894 (0.751–1.000) Ofloxacin resistant 26/111 (23.4%) Moxifloxacin resistant 8/49 (16.3%) Injectable resistant 13/111 (11.7%) 1/57 (1.8%) 0.226 (-0.145–0.597) Amikacin resistant 9/111 (8.1%) Kanamycin resistant 10/92 (10.9%) Capreomycin resistant 6/50 (12.0%) Ethambutol resistant 38/112 (33.9%) 19/57 (33.3%) 0.763 (0.585–0.942) Isoniazid resistant 97/112 (86.6%) 31/57 (54.4%) 0.597 (0.402–0.793) katG and inhA mutations 1/57 (1.8%) katG mutation only 18/57 (31.6%) inhA mutation only 14/57 (24.6%) Pyrazinamide resistant 46/110 (41.8%) Eligible for the shorter regimen Criterion 1 80 (71.4%) Criterion 2 56 (50.0%) Criterion 3 50 (44.6%) Criterion 1: eligible if no resistance to fluoroquinolones and injectables, and no katG or inhA mutations; criterion 2: eligible as per criterion 1 plus no resistance to ethambutol; criterion 3: eligible as per criterion 2 but no katG mutation (see text for details). #: the denominators vary as not necessarily all 112 strains underwent testing for all the drugs due to lack of reagents.
Vol 51 Issue 3
Table of Contents
Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico
